文献速递耳科与耳神经小儿耳鼻咽喉

儿童癌症幸存者及其家长在化疗致感音神经性听力损失中的决策制定

Patient and Parent Decision-Making in the Setting of Chemotherapy-Induced Sensorineural Hearing Loss.
PubMed 文献 · Ear Hear · 2020-01-01

本研究通过半结构化访谈探讨儿童癌症幸存者(CCS)及其家长在化疗致感音神经性听力损失(SNHL)后决定是否使用助听器时的决策过程与需求。访谈7位家长和6位CCS,归纳出CCS的四个主题和家长的四个主题(含两个独特主题),并识别出早期教育、开放沟通和友好解释听力图等未满足需求。

要点

  • CCS希望个性化教育和治疗,并积极参与共同决策
  • 家长更常将决策置于已经历的癌症创伤背景中
  • 需早期、持续提供迟发效应风险教育并用友好语言解释听力图

核心结论

  • 理解CCS和家长对决策过程的看法应纳入癌症相关SNHL的助听器咨询。
  • 应早期持续提供迟发效应教育、开放沟通听力损失风险并改进听力图解释。
  • 这些发现可为开发决策辅助工具以减少决策冲突提供依据。

研究设计与样本

  • 采用基于渥太华决策支持框架的半结构化访谈,录音并逐字转录。
  • 纳入标准为8至30岁、Chang分级>1b的SNHL且已结束治疗的CCS,其家长也可入选;排除活动性疾病患者。
  • 对叙事定性数据采用归纳内容分析。

主要发现

  • CCS组主题包括:理解耳毒性SNHL、渴望个性化教育和治疗、在共同决策中发挥积极作用、接受助听器需要时间和努力。
  • 家长组共享CCS组的第一和最后一个主题,并有两个独特主题:需要专家尊重个体接受SNHL的历程、超越癌症经历走向接受。
  • 家长更常将决策置于已经历癌症创伤的背景中,而CCS则不然。
  • CCS表达了对助听器的身体担忧,如耳部不适和适应音量困难。
  • 识别的需求包括:早期反复强化的迟发效应风险教育、提供者与CCS及家长间的开放沟通、以患者和家长友好语言解释听力图结果。

临床怎么用

  • 在癌症相关SNHL的助听器咨询中,应考虑CCS和家长对决策过程的视角。
  • 应早期且持续提供迟发效应教育,并开放沟通SNHL风险。
  • 应改进听力图结果的传达方式,使用患者和家长友好的语言。
  • 可开发决策辅助工具以减少该人群的决策冲突。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Children with malignancies may be exposed to ototoxic therapies resulting in sensorineural hearing loss (SNHL). There is no consensus as to when intervention with amplification is necessary due to a variety of factors such as disease status, speech and language development, perceived difficulty with communication, and limitations of technology to fit these challenging losses. The decision to proceed with amplification after cancer can be difficult for patients and families. The purpose of this study is (1) to understand the decision-making (DM) process of childhood cancer survivors (CCSs) with SNHL and their parents and (2) to identify their decisional needs. DESIGN: Semi-structured interviews guided by the Ottawa's decision support framework were recorded and transcribed verbatim. Inclusion criteria were CCSs ages 8 to 30 years old with a Chang grade >1b SNHL and off-therapy; parents of this group were also eligible. Patients with active disease were excluded. Prompts inquired of sources of decisional conflict, role in DM, and DM behaviors. Inductive content analysis of the narrative qualitative data was used. RESULTS: Seven parents of CCSs and 6 CCSs participated. Themes in the CCS group included: (1) making sense of ototoxic SNHL; (2) desiring personalized education and treatment of SNHL; (3) playing an active role in the joint DM process; and (4) accepting hearing aids requires time and effort. The parent group shared the first and last theme with the CCS group and had two unique themes: (1) needing experts to respect the individual's journey to SNHL acceptance and (2) moving past the cancer experience to acceptance. Parents more often framed their DM within the context of already experiencing the trauma of cancer, whereas CCSs did not. One parent said, "You see all the rubble and you've lived through the devastation of the storm, but now you got to figure out what's broken." CCSs expressed bodily concerns regarding amplification, such as discomfort to the ear and difficulty in adjusting to the volume. The following needs were identified: early, re-enforced education regarding late effects risks; open communication among providers, CCSs, and parents; and audiogram result interpretations in patient- and parent-friendly language. CONCLUSIONS: Understanding the DM process from the CCS and parent's perspectives should be considered when providing counseling for hearing amplification in the setting of cancer-related SNHL. Earlier and consistent delivery of late effects education, open communication regarding risk for SNHL, and improved delivery of audiogram results should be targets for meeting unmet needs. These findings should inform the development of decision aids to reduce decisional conflict in this population.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Schulz GL, Hayashi S, Spence A, et al. Patient and Parent Decision-Making in the Setting of Chemotherapy-Induced Sensorineural Hearing Loss. Ear Hear. 2020. PMID: 33136642. doi:10.1097/AUD.0000000000000886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。